What factors predict a recurrence of venous thromboembolism or bleeding in adult cancer patients?
For adult cancer patients who have had a venous thromboembolism (VTE), the two main concerns are whether the clot will come back (recurrent VTE) and whether blood-thinning medication will cause dangerous bleeding. Research has identified several factors that help predict these risks. The strongest predictors include a patient's history of VTE, their overall health and cancer stage, the type of cancer, and certain blood biomarkers. Knowing these factors helps doctors tailor treatment decisions, such as how long to continue anticoagulation.
What the research says
A large meta-analysis of 33 studies involving nearly 97,000 cancer patients with VTE identified several factors with high certainty that increase the risk of recurrent VTE. These include a previous history of VTE (adjusted hazard ratio [aHR] 1.50), poor performance status (ECOG >0: aHR 1.81; ECOG >1: aHR 2.44), advanced cancer (aHR 1.38), and specific cancer sites: lung (aHR 1.78), hepatobiliary (aHR 2.37), pancreas (aHR 3.20), and genitourinary (aHR 1.38) 2. Conversely, recent surgery (aHR 0.56) and breast cancer (aHR 0.43) were associated with a lower risk of recurrence 2. The same meta-analysis also found factors with high certainty for increased bleeding risk, though the abstract provided is truncated; the full study details bleeding predictors 2.
Additional research from a post-hoc analysis of the AVERT trial looked at blood biomarkers in cancer patients taking apixaban for VTE prevention. Elevated baseline growth differentiation factor-15 was linked to a higher risk of VTE (subdistribution hazard ratio [SHR] 1.36) 4. Elevated N-terminal pro-B-type natriuretic peptide (SHR 1.44) and C-reactive protein were associated with increased bleeding risk 4. These biomarkers may help refine risk assessment beyond clinical factors alone.
Other studies in different populations highlight additional considerations. For example, subprophylactic anti-Xa levels in critically ill adults receiving low-molecular-weight heparin were associated with a nearly threefold increased odds of VTE (unadjusted OR 2.87) 1. While this study focused on critically ill patients, it underscores the importance of adequate anticoagulation dosing. In stroke patients, VTE risk prediction models show moderate performance but lack external validation 3. These findings are less directly applicable to cancer patients but illustrate the complexity of VTE risk prediction.
For patients without cancer, the VTE-PREDICT risk score uses 14 clinical factors to estimate 5-year risks of recurrence and bleeding, helping guide extended anticoagulation decisions 8. Although developed in non-cancer populations, similar principles apply to cancer patients, where risk-benefit balance is even more critical 910.
What to ask your doctor
- Based on my cancer type and stage, what is my personal risk of having another blood clot?
- Should I have my blood levels of growth differentiation factor-15 or other biomarkers checked to help guide my treatment?
- How does my overall health and activity level (ECOG performance status) affect my risk of recurrence or bleeding?
- What are the signs of bleeding I should watch for while on blood thinners, and when should I seek help?
- How long do you recommend I stay on anticoagulation, and how will we decide when to stop?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.